Home » Newsletters » BioWorld Science

BioWorld Science

March 21, 2016

View Archived Issues

Ember Therapeutics acquires ICX-RHY from Intercytex

68Ga-DOTA-E[c(RGDfK)]2 as potential tracer for tumor angiogenesis imaging

Fujifilm demonstrates potential of Cellnest in bone regeneration

Lilly reports FFA1 receptor agonists for type 2 diabetes

FDA grants orphan drug designation to SPK-TPP1 for the treatment of CLN2 disease

Merck & Co. patents DGAT-2 inhibitors

CTxT Pty discloses PRMT5 inhibitors

FLT3 and JAK inhibitors described in Pierre Fabre patent

Toray Industries introduces IL-23 receptor ligands

CHDI Foundation reports PET probes

Pfizer divulges JAK inhibitors

Anti-Notch 3 ADC from Pfizer shows signs of efficacy in phase I study

Ajinomoto and Mochida to jointly develop AJG-533 in Japan

New role of RUNX3 as a prognostic biomarker for diffuse large B-cell lymphoma

Ono seeks Japanese approval of Opdivo for relapsed or refractory Hodgkin's lymphoma

Cymbalta approved in Japan for chronic lower back pain

New animal model to study the role of Maspin in prostatic intraepithelial hyperplasia

The Garvan Institute of Medical Research receives funding from NHMRC

Sumitomo Dainippon discovers novel orally available human neutrophil elastase inhibitors

Eisai announces discontinuation of sales and voluntary recall of egg white lysozyme preparation

Promising topline data from phase III study of romosozumab in men with osteoporosis

Omnis Pharma and Magnis Therapeutics merge to form Vyriad

Symphogen initiates phase I/II trial of Sym-015 in advanced solid tumor malignancies

miR-122-5p shows promise as a biomarker for liver injury

Affymetrix continues to recommend Thermo Fisher merger following Origin proposal

Proemend approved in Japan for CINV in pediatic patients

ProMIS Neurosciences identifies third therapeutic target for Alzheimer's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...